the #BronchSTART study dashboard beta.microreact.org/project/cTkH24… already contains a huge amount of data
and you can see that there have been unusual regional variations in the RSV season this year 🧵 1/n
normally the RSV season starts in the urban centres of the NW of England and London at around the same time thorax.bmj.com/content/75/3/2… and spreads to the rest of the country in the following 3 weeks 2/n
this year, like in previous ones, RSV did start (early? late?) in the urban centres of the NW of England and peaked at epidemiological week 30 3/n
but unlike previous years London lagged behind, so that the peak here was roughly 4 weeks later (week 34) 4/n
meanwhile in Scotland it's not clear whether a peak has been reached or not, with an unusual double peak pattern that it is tempting to ascribe to schools re-starting 5/n
as even more sites come on board, any interested individual or organisation will be able to track RSV spread at high resolution across the UK and Ireland, and find out at a regional level when (if?) case rates start rising again as we move into the autumn/winter 6/n
and find out how our autumn/winter caseload compares to the summer 7/n
with a variety of factors playing into the near future:
- older susceptible population
- influence of schools opening
- climatic variables
- social distancing measures
it is likely that there will be further surprises 8/n
means that we can track these changes in almost real time
and begin to understand some of the factors putting unprecedented pressure on our primary and secondary care colleagues END
• • •
Missing some Tweet in this thread? You can try to
force a refresh
a few months ago, a group of us, reading reports of unusual patterns of RSV circulation in Australia (a "winter in summer" ncbi.nlm.nih.gov/pmc/articles/P…)
wondered whether the same might happen this year in the United Kingdom and Ireland 🧵1/n
the premise was simple: could we use a simple online questionnaire, collecting only non-patient identifiable information,
to better understand the geographical dynamics and clinical manifestations of RSV circulation in 2021/22?
It turns out we can 2/n
thanks to BronchSTART, a study powered by hundreds of clinicians in Emergency Departments, working as part of the PERUKI Network, we can now watch this year's RSV epidemic play out in real time 3/n
a lot of interest in my thread describing the impact of RSV this year on infants and children in the UK
and questions about whether children are more at risk from RSV or COVID-19 (new🧵) 1/n
RSV (respiratory syncytial virus) is an RNA virus that causes upper and lower respiratory tract infections in children
our recently published review in Vaccine pubmed.ncbi.nlm.nih.gov/33895016/ gives an in-depth introduction to the epidemiology and virology 2/n
In the average year many thousands of children across the UK develop RSV infection: in 2016 there were 36,028 admissions for children <5 in England thorax.bmj.com/content/thorax…@PHardelid with around ~700 intensive care admissions 3/n
just finished nights on call, and found that a toxic triad of RSV, rhinovirus and SARS-CoV-2 is starting to stretch the Scottish hospital I work in to its limits
it's only August
what went wrong? 🧵1/n
Problem 1. We failed to contain SARS-CoV-2. 2/n
This is a Problem for 3 reasons.
Firstly, there are the (very) small number of children with serious SARS-CoV-2 infection. 3/n
in a typical year in England, there are ~36,000 admissions for bronchiolitis (mainly caused by Respiratory Syncytial Virus, RSV) in infants under the age of 1 thorax.bmj.com/content/75/3/2… 3/n
firstly: why should we vaccinate?
-to protect children, who can (rarely) develop severe disease, require hospitalisation, and (very rarely) die
-to protect vulnerable individuals who have contact with children
-to achieve herd immunity: 21% of UK population aged under 18 2/n
secondly, what do we need to vaccinate children?
-a vaccine that robustly protects against severe disease AND prevents transmission
-robust safety data, including paediatric-focused studies & post-licensure monitoring for potential rare outcomes like vaccine-associated MIS-C 3/n